Free Newsletter
SPOTLIGHT: Big Pharma spurns Biogen Idec
Free newsletter via e-mail
Tools
Big Pharma just wasn't big enough to swallow Biogen Idec. A slew of drug makers kicked tires at the biotech company, but eventually concluded that the price was too high; after getting no definitive offers, Biogen took itself off the market. Release
More stories about Biogen Idec
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: